EMVision Medical Devices (ASX: EMV) has reported successful completion of a feasibility study for its First Responder Brain Scanner, de-risking rural stroke use cases and validating scan data quality in flight conditions.
EMVision's First Responder Brain Scanner demonstrated strong operator usability and favourable patient experience during a Royal Flying Doctor Service (RFDS) aeromedical study.
The study, conducted with the RFDS, Australian Stroke Alliance, and South Australian Ambulance Service, saw 17 adult participants enrolled across 15 transfers at 12 airstrips.
Flight nurses rated operator usability favourably across device preparation, patient set-up, and scanner operation.
Patient experience was also positive, with 92% feeling calm during the scan and 100% comfortable seeing the scanner used on a family member.
Pathway to Regulatory Approval De-Risked
Importantly, scan data quality remained as expected and was not materially impacted by flight conditions, even on transfers spanning 125km to 371km from Adelaide Airport.
The median scan time was 5 minutes 7 seconds, which included a 3-minute built-in redundant scan sequence, and the company expects production-equivalent devices to reduce this duration.
These findings support progression to production-equivalent commercial units for subsequent data collection and substantial equivalence testing, crucial steps for regulatory clearance.
EMVision is not only focused on aeromedical applications but is also preparing for additional pre-hospital studies beyond this setting.
This includes concluding the Mobile Stroke Unit (MSU) Stage 1 and preparing for a standard road ambulance study, expanding the evidence base for its devices across various emergency environments.
Continued Funding Support
The company confirmed receipt of a $400,000 non-dilutive milestone payment under the Australian Stroke Alliance project.
This payment provides further funding to support the progression of the First Responder device towards production-equivalent units for regulatory testing.
EMVision has consistently secured non-dilutive funding to advance its projects, recently receiving confirmation of a $1.17 million non-dilutive instalment under the Industry Growth Program in May 2026.
As at 31 March 2026, EMVision reported holding $18.4 million in cash reserves, further bolstered by these recent grant receipts.
Outlook and Risks
The successful aeromedical study is a significant de-risking event for EMVision's First Responder device, validating its use in challenging environments and supporting its regulatory pathway.
However, ongoing challenges include executing further clinical trials, particularly the complexity of acute ischaemia detection within the emu Pivotal Trial, transitioning to production, and securing continued funding through milestone achievement.
The company remains dependent on successful development progress to translate R&D into commercialisation, and future grant instalments are contingent on meeting agreed milestones.
